Our team was delighted to unite with fellow fundraisers at South Africa’s Walk the Talk, raising funds for local charities. Clintec SA chose to support the fight against TB, being heavily involved in monitoring TB studies.
TB is one of the top 10 causes of deaths worldwide, with a significant prevalence in low-middle income countries. TB affects all ages, though adults in their most productive years are highest risk. The most signification causation is observed in patients with compromised immunity, where TB accounts for 40% of HIV/AIDs and 8% of smoker deaths.
Treatment for TB
First-line treatment is entrusted to isoniazid and rifampicin, the 2 most powerful & globally accessible TB drugs. However, as with most viral epidemics, challenges of curing TB are growing with rifampicin- or multidrug-resistant TB (MDR/RR-TB). In 2016, 4.1% of new and 19% of previously treated TB cases in the world are drug resistant. Current MDR-RR TB therapies are not easily accessible and often require up to 2 years of expensive and difficult therapy. With the emergence of 600,000 new cases and 240,000 deaths of MDR-RR TB in 2016 alone, the need for accessible and painless therapies is evident, and a challenge Clintec is proud to be meeting.
On the Front Lines
With a strong presence in Sub-Saharan Africa and APAC, Clintec is well positioned to conduct and support Clinical Research into MDR/RR-TB. We have managed activities for our sponsors across 4 studies in Ethiopia, Kenya, South Africa, Tanzania, Uganda.
Social Corporate Responsibility
14 of our staff Walked the Talk this year and had a fun time uniting with fellow walkers in a cause that truly resonates with Clintec. Thank you to all involved for organising and creating a truly remarkable walk. We are looking forward to sharing the experience with you all once more next year.
You can find more information on these topics below:
Walk the Talk: http://walkthetalk.co.za/
If you have a study which would benefit from Clintec’s wide footprint and expertise in the region, or globally, get in touch with us at [email protected].